Investors

GSK delivers full year and Q4 2022 Results

Quarterly results Listen to the recording of the webcast
Close Video

Our strategy

We make innovative vaccines and specialty medicines to prevent and treat disease. Our R&D focuses on the science of the immune system, human genetics and advanced technologies.

Our R&D focus is on four therapeutic areas: infectious diseases, HIV, oncology, and immunology.

Infectious diseases
1 in 3
of us will be affected by shingles in our lifetime
Go to infectious diseases
HIV
38m
people are living with HIV worldwide
Go to HIV
Immunology
25yrs
of leading research to help people with inflammatory conditions
Go to immunology
Oncology
~10m
people died from cancer in 2020, making it a leading cause of death worldwide
Go to oncology
Behind the science

Discover how we're getting ahead

Human and mouse bilological tissue testing. Immunology. Flow Cytometry. Testing bloods and different

AI and ML power better predictions for patient impact
Lab worker adjusting glasses

Digital twin: using advanced technology to accelerate vaccine development

‘The roar I hear is the next stage of the rocket firing’: MAPS technology and the new age of vaccine development
Person setting up gene therapy machine

Combining genetics and tech to double success rates
R&D scientist working in cell and gene therapy in biology smart laboratory.

Getting ahead of infectious diseases with advanced technology
UK data centre at Stevenage - building 16

Tech for T-cells single cell RNA seq measures shifts in immune cells to pinpoint causes of disease
GSK quality lab team discussion around screens.

Fresh insights could finally help us tackle RSV

The ‘tripledemic’ will hit older people hard this winter – but there are things we can all do to reduce the impact

Read our magazine

Life at GSK

How we help people thrive 

Studio portrait - light background - 8

Culture

At GSK, culture is something we all own. It’s powered by the little things GSK people do every day to help us get ahead of disease together. It drives delivery of our strategy and makes GSK a place people can thrive. Being ambitious for patients, accountable for impact and making sure we always do the right thing is how we deliver for patients, shareholders, and of course the people who work here.

The Code     Purpose, strategy and culture

Man smiling

Growth

Helping people grow professionally and personally is fundamental to GSK. Because we know when individuals grow, our company grows too. Everyone at GSK is encouraged to drive their development through a blend of on-the-job experiences, plus best-in-class formal and informal learning.

Life at GSK

Man smiling

Diversity, equity and inclusion

We’re dedicated to diversity, equity and inclusion in what we do and how we do it. Because it's the right thing to do and it helps us perform better. That’s why we focus on recognising and making the most of our differences and encourage everyone to bring their authentic selves to work. We make sure everyone gets equal opportunities and we’re fully committed to ensuring our workforce reflects the communities in which we work.

Diversity, equity and inclusion

Scientists conversing over skeletal formulae

Wellbeing

We prioritise personal wellbeing so that our people can thrive both in and out of work. We achieve this by fostering a healthy and safe working space for them to succeed and grow. Above all, working at GSK means working with colleagues, friends and managers who support, motivate and care for one another every step of the way.

Life at GSK

Careers at GSK
icon

Outstanding people

Kumaran 1280
INNOVATING TOGETHER 2021
Meet Kumaran: using mRNA technology to develop vaccines
Meg 1280
INNOVATING TOGETHER 2022
Meet Meg: collaborating to do more
Katie 16X9 Web Image Copy
INNOVATING TOGETHER 2022
Meet Katie: using big data to help more patients
GSK OP 16X9nancy 8
INNOVATING TOGETHER 2022
Meet Nancy: igniting change & innovation for patients living with Respiratory Syncytial Virus (RSV)
Pal 1280
INNOVATING TOGETHER 2022
Meet Pal: combining the power of genetics and genomics
Doug
MY GSK STORY
Meet Doug: using data to inform GSKs decisions
View all series

Positively impacting society and the planet

Baby laughing

Pricing and access

We are making our products affordable and available to more people around the world through responsible pricing, strategic access programmes and partnerships.

Scientist inspecting a vial

Global health and health security

We are committed to using our science, our partnerships, and the knowledge we’ve gained from addressing the world’s biggest health challenges to improve health globally.

Scientist in laboratory

Diversity, equity and inclusion

Our work supports the health of all kinds of people. To meet our diverse patients' needs better, we need diversity in our clinical trials and to support our own people to thrive as part of an inclusive team.

Young girl leaving front door

Environmental sustainability

We are working towards a net zero impact on climate and a net positive impact on nature by 2030, across our full value chain.

Scientist in conversation

Product governance

Ensuring the quality, safety and reliable supply of our products is critical to our purpose of uniting science, talent and technology to get ahead of disease together.

Group of scientists in the lab

Ethical standards

Our culture guides our people to do the right thing and act on any concerns they have.

In the spotlight

Investors

GSK delivers strong Q3 2022 sales of £7.8 billion +18% AER, +9% CER and Total EPS 255.9p +>100% AER, +>100% CER; Adjusted EPS of 46.9p +25% AER, +11% CER

Media

GSK announces new global headquarters in central London

Media

GSK tops Access to Medicine Index (ATMI) for eighth consecutive time​

INVESTORS

We announced our full year and fourth quarter 2022 results on Wednesday 1 February 

View latest results

Continue to Company

Back to top